Literature DB >> 11889317

Liquid ventilation with perflubron in the treatment of rats with pneumococcal pneumonia.

Eric W Dickson1, Stephen O Heard, Thomas E Tarara, Jeffry G Weers, Angela B Brueggemann, Gary V Doern.   

Abstract

OBJECTIVE: To determine the efficacy of liquid ventilation using a medical-grade perfluorocarbon (perflubron) combined with parenteral or intratracheal antibiotics in a rat model of pneumonia.
DESIGN: Prospective, laboratory investigation.
SETTING: Experimental laboratory in a university medical center.
SUBJECTS: Wistar rats (n = 112).
INTERVENTIONS: One day after intratracheal inoculation with Streptococcus pneumoniae, rats received one of five experimental treatments or no treatment (control): modified liquid ventilation (MLV), intramuscular ampicillin, MLV plus intramuscular ampicillin, MLV with intratracheal ampicillin, or MLV plus ampicillin PulmoSpheres.
MEASUREMENTS AND MAIN RESULTS: Animals receiving MLV plus intramuscular ampicillin, MLV with intratracheal ampicillin, or MLV plus ampicillin PulmoSpheres had significantly improved 10-day survival rates (85%, 72%, and 72%, respectively) compared with all other groups (0% to 25%).
CONCLUSIONS: MLV in combination with either intramuscular, intratracheal, or PulmoSpheres ampicillin improved survival as compared with MLV alone or the same dose of antibiotics delivered intramuscularly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889317     DOI: 10.1097/00003246-200202000-00021

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  4 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

2.  Unsteady propagation of a liquid plug in a liquid-lined straight tube.

Authors:  Hideki Fujioka; Shuichi Takayama; James B Grotberg
Journal:  Phys Fluids (1994)       Date:  2008-06-24       Impact factor: 3.521

Review 3.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Authors:  David E Geller; Jeffry Weers; Silvia Heuerding
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-11       Impact factor: 2.849

4.  Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.

Authors:  Ryan A Orizondo; Charlene Irvin Babcock; Mario L Fabiilli; Leonid Pavlovsky; J Brian Fowlkes; John G Younger; Keith E Cook
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-01-29       Impact factor: 2.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.